Trial · NCT02355821
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 32
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Collagen Type 1 C-telopeptide | Moxonidine | Baseline | 0.4 | Inter-Quartile Range 0.3 to 0.5 | ng/ml |
| Collagen Type 1 C-telopeptide | Bisoprolol | Baseline | 0.4 | Inter-Quartile Range 0.3 to 0.6 | ng/ml |
| Collagen Type 1 C-telopeptide | Moxonidine | 12 months | 0.3 | Inter-Quartile Range 0.2 to 0.4 | ng/ml |
| Collagen Type 1 C-telopeptide | Bisoprolol | 12 months | 0.4 | Inter-Quartile Range 0.3 to 0.5 | ng/ml |
| Osteocalcin | Moxonidine | Baseline | 18.2 | Inter-Quartile Range 12.4 to 21.9 | ng/ml |
| Osteocalcin | Bisoprolol | Baseline | 19.4 | Inter-Quartile Range 12.4 to 26.2 | ng/ml |
| Osteocalcin | Moxonidine | 12 months | 19.6 | Inter-Quartile Range 15.4 to 23.5 | ng/ml |
| Osteocalcin | Bisoprolol | 12 months | 18.7 | Inter-Quartile Range 12.8 to 22.79 | ng/ml |
| Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL). | Moxonidine | Baseline | 0.109 | Inter-Quartile Range 0.06 to 0.18 | pmol/ml |
| Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL). | Bisoprolol | Baseline | 0.133 | Inter-Quartile Range 0.06 to 0.182 | pmol/ml |
| Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL). | Moxonidine | 12 month | 0.09 | Inter-Quartile Range 0.05 to 0.17 | pmol/ml |
| Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL). | Bisoprolol | 12 month | 0.111 | Inter-Quartile Range 0.07 to 0.163 | pmol/ml |
| Bone Mineral Density (BMD) Using Control Dual-energy X-ray Absorptiometry | Moxonidine | Baseline | -1.0 | Inter-Quartile Range -1.7 to -0.2 | g/cm2 |
| Bone Mineral Density (BMD) Using Control Dual-energy X-ray Absorptiometry | Bisoprolol | Baseline | -0.55 | Inter-Quartile Range -1.3 to -0.2 | g/cm2 |
| Bone Mineral Density (BMD) Using Control Dual-energy X-ray Absorptiometry | Moxonidine | 12 months | -0.6 | Inter-Quartile Range -0.9 to -0.1 | g/cm2 |
| Bone Mineral Density (BMD) Using Control Dual-energy X-ray Absorptiometry | Bisoprolol | 12 months | -1.2 | Inter-Quartile Range -1.9 to -0.75 | g/cm2 |
| Telomerase Activity | Moxonidine | Baseline | 0.87 | Inter-Quartile Range 0.16 to 1.18 | arbitrary units |
| Telomerase Activity | Bisoprolol | Baseline | 0.89 | Inter-Quartile Range 0.16 to 1.15 | arbitrary units |
| Telomerase Activity | Moxonidine | 12 months | 1.15 | Inter-Quartile Range 0.74 to 1.59 | arbitrary units |
| Telomerase Activity | Bisoprolol | 12 months | 0.64 | Inter-Quartile Range 0.46 to 1.01 | arbitrary units |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02355821/results